Related Experiment Video
Updated: May 10, 2026
15:05
Functional Evaluation of Biological Neurotoxins in Networked Cultures of Stem Cell-derived Central Nervous System Neurons
Published on: February 5, 2015
Progress in the development of enzyme-based nerve agent bioscavengers
Florian Nachon1, Xavier Brazzolotto, Marie Trovaslet
1Institut de Recherche Biomédicale des Armées, BP87, 38702 La Tronche Cédex, France.
Chemico-Biological Interactions
|July 2, 2013
Summary
Bioscavengers, enzymes that neutralize nerve agents, offer a promising alternative to current acetylcholinesterase inhibitors. Research focuses on enhancing human and non-human enzymes for improved medical countermeasures against nerve agent toxicity.
Area of Science:
- Biochemistry
- Toxicology
- Enzymology
Background:
- Acetylcholinesterase is the primary target for nerve agent toxicity.
- Current protective strategies using reversible inhibitors have limitations, including peripheral protection only and potential side effects.
- An alternative strategy involves scavenging nerve agents in the bloodstream before they reach acetylcholinesterase.
Purpose of the Study:
- To review the development of bioscavengers as novel medical countermeasures against nerve agents.
- To discuss various types of bioscavengers, including stoichiometric and catalytic enzymes.
- To highlight challenges and potential solutions for improving bioscavenger efficacy and applicability in humans.
Main Methods:
- Review of existing literature on bioscavenger research and development.
- Discussion of different enzyme classes (human and non-human) investigated for nerve agent detoxification.
- Exploration of strategies to overcome challenges such as immunogenicity and limited enzyme lifetime.
Main Results:
- Human butyrylcholinesterase is a leading stoichiometric bioscavenger, with ongoing efforts in mass production and regeneration.
- Human paraoxonase 1 is a leading catalytic bioscavenger, with research focused on enhancing its efficiency against toxic nerve agent isomers.
- Non-human enzymes like phosphotriesterases and diisopropylfluorophosphatase show potential but face immunogenicity challenges, with modifications like PEGylation being explored.
- Gene therapy for in situ bioscavenger generation is a future possibility with established proof of concept.
Conclusions:
- Bioscavengers represent a significant advancement in medical countermeasures against nerve agents.
- Both stoichiometric and catalytic bioscavengers, primarily human enzymes, are under active development.
- Addressing challenges like immunogenicity and enzyme stability is crucial for clinical translation, with various strategies being investigated.
Keywords:
2-(o-cresyl)-4H-1,3,2-benzodioxaphosphoran-2-one or cresyl saligenin phosphateAChEBChEBioscavengerCBDPCHOCaEChEChinese hamster ovaryHDLMedical countermeasuresNerve agentOPNAOrganophosphate poisoningPEGPRADPTEPretreatmentTMPPTOCPTreatmentacetylcholinesterasebutyrylcholinesterasecarboxylesterasecholinesterasehPON-1high density lipoproteinhuman paraoxonaseorganophosphorus nerve agentphosphotriesterasepolyethyleneglycolproline rich attachment domaintrimethylolpropane phosphate or ethyl bicylclophosphatetriorthocresylphosphateMore Related Videos
Related Concept Videos
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...